OP 2507

Drug Profile

OP 2507

Alternative Names: ONO 2507

Latest Information Update: 04 Oct 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Pharmaceutical; Ono Pharmaceutical
  • Class Anti-ischaemics; Hepatoprotectants; Prostaglandins; Small molecules
  • Mechanism of Action Epoprostenol agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cerebrovascular disorders; Liver disorders; Reperfusion injury

Most Recent Events

  • 04 Oct 2000 Two preclinical studies have been added to the Transplant Rejection and Vascular Disorders pharmacodynamics sections ,
  • 14 Jun 2000 Discontinued-Preclinical for Reperfusion injury in Japan (IV)
  • 30 May 2000 Discontinued-II for Liver disorders prevention in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top